Puma Biotechnology develops and sells cancer treatments, including the breast cancer drug NERLYNX. PBYI reports earnings on Thu, Nov 5, 2026.
Prices, price targets and earnings estimates for PBYI are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in PBYI in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PBYI is in one of them and how their past PBYI trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company based in Los Angeles, California, that develops and sells cancer treatments. Its main commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain types of HER2 positive breast cancer. In the United States the company markets NERLYNX through its own sales force, and it works with partners in other countries to sell the drug there. It is also developing alisertib, an investigational cancer drug aimed at small cell lung cancer and hormone receptor positive breast cancer.
